parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in smooth muscle cells	0.75
chemistry Open Targets	compounds already reach it: tenatumomab, f16il2	0.81
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	5 Parkinson's papers of 3,781	0.76
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 9639

receipt 9648: TNC in dopamine neurons, braak

power: full sample -0.29 (p 0.250, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.232, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.086, n 18). could be the mix.
skeptic: leave-one-out range -0.41 to -0.19, sign flips 0; without severely affected donors -0.29 (p 0.250, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TNC in dopamine neurons.

case closed: nothing better to follow up.

receipt 9647: TNC in astrocytes, braak

power: full sample -0.09 (p 0.722, n 18), 95% CI -0.53 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.07 (p 0.774, n 18). could be the mix.
skeptic: leave-one-out range -0.23 to +0.02, sign flips 2; without severely affected donors -0.09 (p 0.722, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TNC in astrocytes.

case closed: nothing better to follow up.

loading the receipts